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Most patients in palliative care have problems with dry mouth caused by medica-
tion or as a direct result of their condition. Dry mouth may cause problems that
affect the primary disease negatively and contribute to poorer quality of life in pal-
liative patients. This randomized controlled trial compared the efficacy of three dif-
ferent oral moisturizers: 17% watery solution of glycerol; oxygenated glycerol
triester (marketed as Aequasyal in Europe and as Aquoral in the USA); and a
newly developed product, Salient. Of the three products, glycerol provided the best
relief from xerostomia directly after application, but had no effect after 2 h. By con-
trast, the effects of Aequasyal and Salient were largely maintained over the same
period. The findings for oral discomfort and pain and speech problems showed a
similar pattern. Despite its poor effect after 2 h, patients preferred glycerol over
Salient and Aequasyal, probably because of the unpleasant taste of Aequasyal and
the consistency and mode of application of Salient. Within the limitations of this
study, none of the three products tested was found to be clinically completely ade-
quate. However, the glycerol solution was preferred by this group of patients, and
its short-lived effect can be compensated for by frequent applications.
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Saliva plays a fundamental role in maintaining oral
health. Healthy individuals produce resting (unstimu-
lated) whole saliva at a rate of 0.3–0.4 ml min1. The
subjective feeling of xerostomia is thought to occur when
less saliva is secreted than the amount of water lost from
the mouth by evaporation and by absorption through
the oral mucosa (1). Mucin-rich resting saliva lubricates
mucous membranes and teeth, and stimulated saliva
plays an important role in mastication, speech, swallow-
ing, and digestion. Constituents such as lactoferrin,
peroxidase, and histatin contribute to salivary antimicro-
bial, antiviral, and antifungal properties (2). In individu-
als with failing salivation, these important properties of
saliva in the oral cavity are reduced or absent, causing
dry and sore mucous membranes, delayed wound heal-
ing, rapid development of caries and erosion, fungal
infections of the mouth and throat, discomfort, pain, and
problems using dentures (2). Dry mouth can also lead to
swallowing difficulties, speech disturbances, loss of appe-
tite, dehydration, and malnutrition, thus having a nega-
tive effect on diseases and contributing to reduced
quality of life, particularly in life’s final phase (3).
Palliative care is the active treatment and care for
patients with incurable diseases and short life expec-
tancy. Relief of the patient’s physical pain and other
distressing symptoms is central, together with measures
aimed at relieving psychological, social, and spiritual/
existential problems. The goal of palliative care is the
best possible quality of life for patients and their fami-
lies (4). In some guidelines, the palliative care patient
population is defined to include patients with a life
expectancy of <9–12 months. In reality, the palliative
phase starts when it is recognized that the disease is
incurable, and it ends when the patient dies. In Nor-
way, palliative care patients with advanced disease may
be transferred to a specialist palliative care unit, at
either a hospital or a nursing home, when there is a
wish or need for extended care. The term ‘terminal’
may be confused with the term ‘palliative’, but the for-
mer refers primarily to the last few hours or days
before death (5). It is difficult to predict when death is
likely to occur. However, by applying the World
Health Organization (WHO) performance status scale,
which ranges from grade 0 (the patient is fully active
and able to carry on all predisease performance without
restriction) to grade IV (the patient is completely dis-
abled, cannot carry on any self-care and is totally con-
fined to bed or chair) (6), the cause of the patient’s
decline can be described. About 95% of patients in pal-
liative care in Norway are cancer patients (7).
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Many patients in palliative care have received treat-
ment or medications that may have adverse effects on
oral health. In addition to radiation and chemotherapy
to the head/neck, drugs with anticholinergic and/or
sympathomimetic effects, opioids, glucocorticoids, and
bisphosphonates may have an unfavourable impact on
oral health (8). In the last phase of life, an opioid anal-
gesic (morphine), a sedative (midazolam), an antiemetic
(haloperidol), and an antisecretory agent (glycopyrro-
late) are commonly given subcutaneously to relieve
symptoms and may be combined (9). Other disease-re-
lated factors that may have adverse effects on oral
health are dehydration, difficulties in chewing, impaired
immune response, unfavourable changes in bacterial
flora and secondary infections, anxiety and depression,
impaired motor function, and an inability to self-care
(10–12).
A range of different products are used in an effort to
alleviate the symptoms of dry mouth. There are several
commercially available mouthwashes and gels. In addi-
tion, there are many products that are used based on tra-
dition and experience, such as tea, vegetable oil, and
cream, and watery solutions of glycerol in different con-
centrations (13). A Cochrane review from 2011 con-
cluded that there was no strong evidence that any topical
therapy is completely effective for relieving the symptoms
of dry mouth. However, one product, oxygenated glyc-
erol triester (OGT), was shown to be somewhat more
effective than an aqueous electrolyte solution (Saliveze)
(14). The present paper reports findings from a random-
ized controlled trial (RCT) in which the efficacy of three
moisturizers [17% watery solution of glycerol, OGT, and
a newly developed product (Salient)] was compared.
The trial was designed to answer the following ques-
tion: Do any of the three agents improve xerostomia,
reduce pain and discomfort, and improve ability to talk
in palliative care patients? The hypothesis was that
there was no difference in efficacy between 17% glyc-
erol, OGT, and Salient.
Material and methods
The study was designed as an RCT (Fig. 1) with a cross-
over design (Fig. 2), and was performed according to the
Consolidated Standards of Reporting Trials (CONSORT)
guidelines (15). All patients were treated with three oral-
care products. A block randomization was applied for the
sequences (1–6) in which the patients would receive the
different products (Fig. 2). The project leader (GVS) gen-
erated the intervention sequences. The study was con-
ducted by the Institute of Clinical Dentistry, Faculty of
Medicine, University of Bergen, Norway.
A sample size of 30 individuals per product was calcu-
lated to be sufficient based on crude chi-square tests with
dichotomous outcomes based on an expected 40% differ-
ence between two of the products. As no similar study
with relevant effects was found, this was considered a clini-
cally relevant effect. The calculations did not take into
account the use of the full ordinal Likert scale in the anal-
yses or the fact that all patients received all products in a
crossover design.
Thirty patients were recruited from two palliative care
units (at Haraldsplass Deaconess Hospital and the Red
Cross Nursing Home, in Bergen, Norway) (Fig. 1). A nurse
at each unit was in charge of enrolling patients who met the
eligibility criteria. Of the 34 eligible patients who were
enrolled, 30 were selected by the project leader GVS (Fig. 1).
Eligibility criteria for participants were: xerostomia (sub-
jective feeling of dry mouth); in institutionalized palliative
care; curative treatment of existing diseases completed or
terminated; WHO performance status ≥III (corresponding
to Karnofsky Performance Status Score of 30%–40% (i.e.,
only capable of limited self-care, confined to bed or chair
more than 50% of wake time); cognitively functioning, cap-
able of and willing to give written consent, capable of giving
responses to a limited questionnaire; and expected to remain
at the care centre for a minimum of 3 d. Patients who had
Fig. 1. Flow diagram of the different phases (enrolment, allo-
cation, follow-up, and analysis) of the study [performed
according to Consolidated Standards of Reporting Trials
(CONSORT)].
Fig. 2. Schematic diagram of the clinical intervention from
baseline to the end.
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previously been treated with chemotherapy and/or radio-
therapy to the head and neck region were excluded.
All participants received verbal and written information
by the project leader on the purpose of the study, how it
would be carried out in practice, and the potential benefits
and side-effects of the products. The intervention started
as soon as the consent form was accepted and signed.
The project leader assigned the participants to the inter-
ventions. The intervention was, in general, carried out
after morning routine care and breakfast. Each product
was applied at the same time of day to avoid the risk that
diurnal variation in health status might influence the out-
come.
If the patient agreed to participate, he/she answered a
short questionnaire, which contained the primary outcome
measures of subjective xerostomia, discomfort and pain,
and speech problems. These measures were recorded on a
5-point ordinal Likert scale at three points in time: before
the intervention; immediately after the intervention; and
2 h after the intervention (Fig. 2). In addition, evaluations
of taste and application method of the products used were
recorded on a 3-point ordinal scale. The actual wordings
of all categories are shown in Figs. 3–6. After all products
had been applied and procedures completed (2 h after the
last intervention, normally on day 3), patient preference of
the three products was recorded on a 4-point nominal
scale on the same questionnaire. At the same time, the
patients were asked to comment freely on the products
and procedures. Demographic characteristics, medical his-
tory, and medications were registered in a personal and
health information form (Table 1).
The products were presented in neutral containers with-
out labels, ensuring that the patients were blinded as to
their content. The dentist who carried out the intervention
could not be similarly blinded because of the differences in
application methods for the three products.
The three products compared in this study were: (i) a
17% watery solution of glycerol (not a patented com-
pound; Sanivo Pharma, Oslo, Norway; Batch no.
17A121); (ii) Oxygenated glycerol triester (OGT) (Eisai
SAS, Paris, France; Batch no. CH130); and (iii) Salient
(Salient Pharma, Klampenborg, Denmark; Batch no.
715990). The tradename for OGT is Aquoral in the USA
and Aequasyal in Europe (though so far not marketed in
Scandinavia). The product is CE marked, and classified as
a medical device, class I. Salient is a newly developed pro-
duct, which is CE marked and classified as a medical
device, class IA. Salient becomes commercially available in
2019; its main ingredients are polyethylene oxide and
hydroxypropyl methylcellulose.
Fig. 4. Discomfort/pain at baseline, immediately after applica-
tion of product, and 2 h later.
Fig. 5. Speech problems at baseline, immediately after appli-
cation of product, and 2 h later.
Fig. 3. Xerostomia at baseline, immediately after application
of product, and 2 h later.
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A dentist (SFK) performed the procedure as follows. Ini-
tially, lips were lubricated with white Vaseline (petroleum
jelly) and mucosa was cleaned with 0.3% saline solution. The
actual product was then applied. Aequasyal was sprayed
onto the mucosa; glycerol was applied with a soaked gauze
pad on lockable tweezers; and Salient was dispensed to the
patient on a spoon. The night following each application was
considered a washout period, after which a new product
could be applied. The total duration of the intervention was
thus normally 3 d. However, the patient’s condition or other
treatments might necessitate a longer period.
The study was conducted in the period 1 March 2018 to
30 November 2018. The study was approved by the Regio-
nal Committee for Medical and Health Research Ethics,
Northern Norway (REC North ref. no. 2016/2316), and
registered at the Norwegian Social Science Data Services
(NSD), and with ClinicalTrials.gov (ID: NCT03400969).
Statistical analyses
For categorical variables, percentages and frequencies were
reported. To investigate any differences in the Likert scales
between the three oral-care products analysed, marginal
ordinal logistic regression with robust variance estimates
was applied, adjusting P-values for correlation between
the nine repeated observations for each individual. The
ordinal logistic regression allows analyses of the ordered
5-point Likert scale between the oral care products for the
three time points in one joint model. Changes from the
baseline measures for each of the oral care products, and
differences between the products immediately and 2 h after
application, were reported as ORs. To study possible
carry-over effects, differences between products at baseline
the day after they were applied were analysed.
Ordinal regression, with robust variances, was also
applied to analyse differences in the 3-point scales for taste
and application method of the three products. The OR is
interpreted as difference in risk (e.g., between products)
for an ‘increase’ in one level of the Likert scale. To test
whether the distribution of the preferred product was uni-
form for the three, a chi-square test was applied. The sta-
tistical analyses were performed using STATA (version 15;
StataCorp, College Station, TX, USA). Values of P <0.05
were considered statistically significant.
Results
Demographic characteristics, medical history, and
medications of the patient sample are shown in
Table 1. Of the 30 patients, 17 (57%) were female
(mean age = 68 yr) and 13 were male (mean
age = 69 yr). The main diagnosis was cancer in 28
(93%) of the patients; 12 (40%) had WHO perfor-
mance status III and 18 (60%) had status IV.
The effects of the products used on xerostomia are
shown in Fig. 3 and Table 2. Relative to baseline
Fig. 6. Assessment of application method and taste.
Table 1
Demographic and disease-related information for patients















Cancer, locally advanced or metastatic
Gastrointestinal 12












Lung transplant rejection 1
Syringomyelia 1
Kidney failure 1
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recordings, all products produced improvements imme-
diately after the intervention. At this time, a higher
number of respondents treated with glycerol reported
no or minimal oral dryness (indicated by the green
shades of the columns) compared with respondents
treated with Aequasyal. Two hours after intervention,
the effect of glycerol had decreased relative to the other
two products (in fact, had reverted to baseline),
whereas the effects of Aequasyal and Salient largely
persisted.
The effects of the products on the occurrence of dis-
comfort and pain are shown in Fig. 4 and Table 2. Rel-
ative to baseline recordings, all products produced
improvements immediately after the intervention. At
this time, a higher number of respondents treated with
glycerol reported either no or only minimal discomfort
or pain (indicated by the green shades of the columns)
compared with respondents treated with Aequasyal.
Two hours after the intervention, the effect of glycerol
had dropped relative to the other two products and
was no longer different from baseline, whereas the
effects of Aequasyal and Salient largely persisted.
The effects of the products on the occurrence of
speech problems are shown in Fig. 5 and Table 2. Rel-
ative to baseline recordings, all products showed pro-
nounced improvements immediately after intervention.
At this time, there were no significant differences
between the products. Two hours after the intervention,
the effect of glycerol had dropped by a larger amount
than that of the two other products and was no longer
different from baseline, whereas the effects of
Aequasyal and Salient largely persisted.
No statistically significant carry-over effect was dis-
covered for xerostomia, discomfort and pain, or speech
problems (smallest P = 0.13).
Data on the application method of the moisturizers
are shown in Fig. 6 and Table 3. Whereas 22 (73%) of
the 30 patients reported that the application method of
glycerol was agreeable, only a few felt that about
Salient. Aequasyal occupied an intermediate position
between glycerol and Salient.
The data for taste are shown in Fig. 6 and Table 3.
Aequasyal was disliked by 23 (77%) of 30 patients. For
the other products, most respondents reported a neutral
taste. The majority of patients (19/30, 63%) preferred
glycerol (P < 0.001). The corresponding numbers for
Salient and Aequasyal were six (20%) of 30 and three
(10%) of 30, respectively. Two of the patients preferred
not to use any of the three products. There was no
association between the preferred product and on
which day the preferred product was applied
(P = 0.48).
Open-ended comments
All patients commented on the treatment received. The
remarks concerning xerostomia, taste, application
method, and preferred product mirrored those reported
above. The sticky, glutinous consistency of Salient was
mentioned by 18 (60%) of 30 patients. In addition, 11
Table 2
Effect of the three oral care products on primary outcomes, immediately after application and 2 h later
Outcome
Immediately after Two hours later
OR (95% CI) P-value OR (95% CI) P-value
Xerostomia
A: Aequasyal 13.10 (6.15–27.90)B <0.001 8.79 (4.70–16.46)B <0.001
B: Glycerol 38.59 (18.73–79.48)A <0.001 0.93 (0.57–1.51)AC 0.763
C: Salient 16.95 (7.19–39.97) <0.001 9.76 (4.68–20.36)B <0.001
Discomfort/pain
A: Aequasyal 3.35 (1.85–6.06)B <0.001 5.69 (3.20–10.12)b <0.001
B: Glycerol 8.39 (4.12–17.08)A <0.001 1.85 (1.00–3.45)ac 0.051
C: Salient 4.70 (2.63–8.39) <0.001 5.61 (3.15–10.02)b <0.001
Speech
A: Aequasyal 4.89 (2.74–8.73) <0.001 4.86 (2.51–9.40)B <0.001
B: Glycerol 6.07 (3.66–10.07) <0.001 1.18 (0.73–1.89)AC 0.496
C: Salient 5.45 (2.53–11.72) <0.001 5.01 (2.66–9.42)B <0.001
Results represent odds ratio for a change in one level of the Likert scale over time in primary outcomes for the three oral care products.
Statistically significant differences between products immediately after application, and 2 h later, are marked using superscript letters.
Compared with product: A: P < 0.01, a: P < 0.05; B: P < 0.01, b: P < 0.05; C: P < 0.01, c: P < 0.05.
Table 3
Difference in risk (e.g., between products) for a change in one
level of the Likert scale
Variable OR (95% CI) P-value
Application method
A: Aequasyal 1C <0.001*
B: Glycerol 2.52 (0.75–8.47)C 0.135
C: Salient 0.13 (0.04–0.48)AB 0.002
Taste
A: Aequasyal 1BC <0.001*
B: Glycerol 125.56 (13.39–1,177.12)AC <0.001
C: Salient 15.04 (4.4–51.34)AB <0.001
Differences between products are marked using superscript. Com-
pared with product: A: P < 0.01; B: P < 0.01; C: P < 0.01.
*Test of homogeneity.
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(37%) of 30 patients characterized the taste of
Aequasyal as strange, strong, oily, rancid, nauseating,
or disgusting. Others (4/30, 13%) were dissatisfied with
the use of a small spoon when dispensing Salient, and
an equal number of patients commented that the most
important factor for their well-being was oral care in
itself; that is, getting help with brushing their teeth and
cleaning the mucosa.
Discussion
The main findings of this RCT study were that the
17% glycerol solution was the most effective mois-
turiser of the three products in the short term, but had
no effect 2 h after application. Aequasyal and Salient
had longer-lasting effects. A similar pattern was dis-
played for discomfort and pain and speech problems.
The glycerol solution was preferred by the patients.
A problem with artificial saliva is that it is unable to
provide sustained relief for any substantial period of
time (14). Although all three products in this study had
reduced effects after 2 h, only Salient and Aequasyal
showed an improvement in xerostomia over baseline.
Despite the fact that this provides an answer to the pri-
mary objective of the study (i.e., the three products did
improve xerostomia, reduce pain and discomfort, and
improve ability to talk), the two products with the most
sustained effect on xerostomia were, in most cases, not
the patients’ preferred product. The findings for dis-
comfort and pain and speech showed the same ten-
dency: Aequasyal and Salient either had a negligible
reduction or, in the case of Aequasyal, even an
increased effect 2 h after application. Glycerol, on the
other hand, even though it showed the most favourable
effect immediately after application, had the least (or
no) effect after 2 h.
Why the patients, perhaps surprisingly, still preferred
glycerol is probably because of the disagreeable taste of
Aequasyal and the unpleasant sticky consistency of
Salient, reported by a majority of the respondents. This
supposition is strengthened by the fact that no factors,
other than the above, were mentioned in the open-
ended comments.
When evaluating the possible clinical implications of
these findings, the rationale for choice of products
and selection of patients is of importance. Thus,
Aequasyal was chosen because this was the only pro-
duct, in a Cochrane Review from 2011 (14, 16), found
to provide significant relief from dry mouth. Accord-
ing to the manufacturer, Aequasyal adheres to the
oral mucosa, forming a lipid film that protects against
mechanical trauma, and may help to reduce loss of
moisture from the oral tissue and inflammation. A
17% watery glycerol solution was chosen because this
concentration was recommended by ‘helsebib-
lioteket.no’, a public website run by the Norwegian
health authorities that provides health-care profession-
als with recommendations based on available evidence
(17). Glycerol in varying concentrations is used by
36% of Norwegian health institutions (13) and is
inexpensive, easily available, and easy to apply. How-
ever, in some countries (including the USA, the
Netherlands, Great Britain, and Singapore), its use is
not recommended because of possible hydroscopic
properties, which may result in desiccation of the
mucous membranes (18). Salient was chosen because
of the manufacturer’s claim that the combination of
the two main ingredients has a quality described as
spinnbarkeit, best explained as ‘spinnability’ or
‘stretchability’, which appears to be of value in allevi-
ating the symptoms of dry mouth. The ingredients of
Salient are innocuous and commonly used in medica-
tions, cosmetics, and nutrients.
It has been argued that the effect on xerostomia of
various saliva substitutes is related to the aetiology of
the patient’s health status (19, 20). This may be because
salivary gland function is influenced by various factors
and stimuli, which can cause changes in volume, flow,
and composition (21). The reasons why palliative care
patients were selected for this study are twofold: it was
assumed that their need for oral care might be greater
and/or different from less compromised patients; and
that in such patients, possible differences between prod-
ucts might be more discernible.
That palliative care patients were used in this experi-
ment had some implications for the study design. The
frailness of the patients meant that it was necessary to
affect their daily life as little as possible. Hence, only a
few, carefully chosen, questions were asked.
Our ability to generalize from this study is limited.
The study sample was relatively small and only a few
variables were explored. Nevertheless, the sample size
was still sufficient for adequate statistical analyses,
and increasing the sample size would have been
extremely demanding. Recruitment required coopera-
tion of the nursing staff and the severely compro-
mised patients, and the presence of the researcher at
any one time. Another limitation is the assessment of
only one dose of treatment. However, it would be
difficult to conduct such a study on this group of
patients if it interfered more with their daily life than
the present study, considering their short remaining
lifespan.
It is likely that the findings of the present study are
generalizable to similar patients; that is, severely com-
promised patients. On the other hand, the conclusions
drawn from the present select and special population
are not valid for generalization to healthier patients. To
do so, further research would be needed. Similarly, no
conclusions can be drawn from the present study for
products other than those tested.
To the best of our knowledge, studies comparing
different saliva substitutes have never before been per-
formed in palliative care patients, only in less compro-
mised patients with dry mouth problems (19, 20, 22).
However, Aequasyal was previously tested in an RCT
study of psychotropic drug-induced xerostomia (16). In
that sample, only two out of 37 patients found the taste
disagreeable and none reported nausea. This may indi-
cate that the palliative care patients perceive such prod-
ucts differently from healthier patients. Alternatively,
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the psychological status for which they were treated or
the drugs used might be of importance in this context.
It is useful to consider whether any of the three
products could be improved. For Aequasyal, perhaps
the taste problem might be solved chemically. The pre-
sent 17% concentration of glycerol is not based on sci-
entific evidence, but rather on tradition and long-term
experience. A higher concentration, up to 30% (which
may be used without desiccation of the mucosa) (23),
might perhaps produce better sustainability of the
effect. Finally, the way in which Salient was dispensed
could perhaps be improved. Rather than use of a small
spoon for application, which was disliked by some
respondents, use of a spray could be investigated, and
it might be possible to reduce the disagreeable feeling
of stickiness by increasing the water content. In view of
the limited clinical usefulness of the tested products in
their present form, and the plethora of other oral-care
agents that exist, it cannot be precluded that other
products might show different properties and better
clinical outcome. However, so far this does not appear
to be supported by scientific evidence.
It is also useful to consider what properties would be
ideal in a product used for oral care. Based on the pre-
sent findings, a product with a non-nauseating pleasant
taste, texture, and consistency appears paramount,
but a low viscosity and an agreeable application
method may also be important. However, only an in-
depth qualitative investigation among palliative care
patients might provide a comprehensive answer to this
question.
Even though the findings clearly demonstrate signifi-
cant differences among the three products, none had
completely satisfactory clinical properties. However, the
preferred product, glycerol, has the advantage of being
immediately effective and well tolerated by the patients.
It may be possible to compensate, to some extent, for
the drawback of glycerol, namely the short-lived effect,
by frequent applications or higher concentrations.
Regardless, the findings of this study do not contribute
radically to improving guidelines for palliative oral
care.
Within the defined limitations of this study, we con-
clude that none of the three tested products was found
to be clinically completely adequate. The 17% concen-
tration of glycerol had the most positive effect immedi-
ately after application, but little or no effect 2 h
thereafter. Aequasyal and Salient had a long-lasting
effect, but were nevertheless not preferred by the
patients – probably because of the disagreeable taste of
the former and the unpleasant, sticky consistency of the
latter. The need for better products and further
research in order to improve oral care seems obvious.
Of clinical relevance, the glycerol solution was preferred
by this group of patients, and its short-lived effect can
be compensated for by frequent applications.
Acknowledgements – Our greatest gratitude to the patients who
were willing to share some of their last time with us to contribute
to this study. We would also like to thank the health-care person-
nel at Sunniva Centre for Palliative Care, Haraldsplass Deaconess
Hospital, Bergen, and at Røde Kors Nursing Home, Bergen, for
their positivity and willingness to help and share their knowledge.
Conflicts of interest – None to declare.
References
1. DAWES C. How much saliva is enough for avoidance of xeros-
tomia? Caries Res 2004; 38: 236–240.
2. DAWES C, PEDERSEN AM, VILLA A, EKSTROM J, PROCTOR GB,
VISSINK A, AFRAMIAN D, MCGOWAN R, ALIKO A, NARAYANA
N, SIA YW, JOSHI RK, JENSEN SB, KERR AR, WOLFF A. The
functions of human saliva: a review sponsored by the World
Workshop on Oral Medicine VI. Arch Oral Biol 2015; 60:
863–874.
3. ALDRED MJ, ADDY M, BAGG J, FINLAY I. Oral health in the
terminally ill: a cross-sectional pilot survey. Spec Care Dentist
1991; 11: 59–62.
4. WORLD HEALTH ORGANIZATION. WHO definition of palliative
care. Vol. 2018. World Health Organization, 2018.
5. HUI D, NOORUDDIN Z, DIDWANIYA N, DEV R, DE LA CRUZ
M, KIM SH, KWON JH, HUTCHINS R, LIEM C, BRUERA E.
Concepts and definitions for “actively dying”, “end of life”,
“terminally ill”, “terminal care”, and “transition of care”: a
systematic review. J Pain Symptom Manage 2014; 47: 77–89.
6. WORLD HEALTH ORGANIZATION. International Classification of
Functioning, Disability and Health (ICF). Vol. 2018. 2018.
7. NOU 2017:16. Pa liv og død. Palliasjon til syke og døende.
Oslo: Statens forvaltningstjeneste, 2017.
8. WOLFF A, JOSHI RK, EKSTROM J, AFRAMIAN D, PEDERSEN
AM, PROCTOR G, NARAYANA N, VILLA A, SIA YW, ALIKO A,
MCGOWAN R, KERR AR, JENSEN SB, VISSINK A, DAWES C. A
guide to medications inducing salivary gland dysfunction,
xerostomia, and subjective sialorrhea: a systematic review
sponsored by the World Workshop on Oral Medicine VI.
Drugs R D 2017; 17: 1–28.
9. KONGSGAARD U, KAASA S, DALE O, OTTESEN S, NORDOY T,
HESSLING SE, VON HOFACKER S, BRULAND OS, LYNGSTADAAS
A. NIPH systematic reviews: executive summaries. In: Pallia-
tive treatment of cancer-related pain. Oslo, Norway: Knowl-
edge Centre for the Health Services at The Norwegian
Institute of Public Health (NIPH), 2005; 1–254.
10. CARPENTER G. Dry mouth, a clinical guide on causes, effects
and treatment. Berlin, Heidelberg: Springer, 2015.
11. PEDERSEN AM, REIBEL J, NAUNTOFTE B. Primary Sjogren’s
syndrome (pSS): subjective symptoms and salivary findings. J
Oral Pathol Med 1999; 28: 303–311.
12. LOCKER D. Dental status, xerostomia and the oral health-re-
lated quality of life of an elderly institutionalized population.
Spec Care Dentist 2003; 23: 86–93.
13. KVALHEIM SF, STRAND GV, HUSEBO BS, MARTHINUSSEN MC.
End-of-life palliative oral care in Norwegian health institutions.
An exploratory study. Gerodontology 2016; 33: 522–529.
14. FURNESS S, WORTHINGTON HV, BRYAN G, BIRCHENOUGH S,
MCMILLAN R. Interventions for the management of dry mouth:
topical therapies. Cochrane Database Syst Rev 2011; 12:
CD008934. https://doi.org/10.1002/14651858.CD008934.pub2
15. THE CONSORT GROUP. Consort, transparent reporting of
trials. Vol. 2019. Oxford: The CONSORT Group, 2010.
16. MOULY SJ, ORLER JB, TILLET Y, COUDERT AC, OBERLI F,
PRESHAW P, BERGMANN JF. Efficacy of a new oral lubricant
solution in the management of psychotropic drug-induced
xerostomia: a randomized controlled trial. J Clin Psychophar-
macol 2007; 27: 437–443.
17. LISE T, JEAN MP, MERETE H, FROSTAD OS. Munnstell til voksne
pasienter, Vol. 2019. Oslo, Norway: Helsebiblioteket.no, 2016.
18. HOLMES S. Nursing management of oral care in older
patients. Nurs Times 1996; 92: 37–39.
19. VISCH LL, GRAVENMADE EJ, SCHAUB RM, VAN PUTTEN WL,
VISSINK A. A double-blind crossover trial of CMC- and
mucin-containing saliva substitutes. Int J Oral Maxillofac
Surg 1986; 15: 395–400.
Oral moisturizers in palliative care 7
20. VISSINK A, S-GRAVENMADE EJ, PANDERS AK, VERMEY A,
PETERSEN JK, VISCH LL, SCHAUB RM. A clinical comparison
between commercially available mucin- and CMC-containing
saliva substitutes. Int J Oral Surg 1983; 12: 232–238.
21. PEDERSEN AML, SORENSEN CE, PROCTOR GB, CARPENTER
GH, EKSTROM J. Salivary secretion in health and disease. J
Oral Rehabil 2018; 45: 730–746.
22. SKRINJAR I, BORAS VV, BAKALE I, ROGULJ AA, BRAILO V,
JURAS DV, ALAJBEG I, VRDOLJAK DV. Comparison between
three different saliva substitutes in patients with hyposaliva-
tion. Clin Oral Investig 2015; 19: 753–757.
23. ROWE RAYMOND C, SHESKEY PAUL J, QUINN MARIAN E. Hand-
book of pharmaceutical excipients. London, UK: RPS Publish-
ing, 2009; 283–286.
8 Kvalheim et al.
